Home > Publications database > Design and Preclinical Characterization Program toward Asundexian (BAY 2433334), an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic Disorders > print

001     600501
005     20250724132647.0
024 7 _ |a 10.1021/acs.jmedchem.3c00795
|2 doi
024 7 _ |a 0095-9065
|2 ISSN
024 7 _ |a 0022-2623
|2 ISSN
024 7 _ |a 1520-4804
|2 ISSN
024 7 _ |a 1943-2992
|2 ISSN
024 7 _ |a 10.3204/PUBDB-2023-08014
|2 datacite_doi
024 7 _ |a altmetric:154114745
|2 altmetric
024 7 _ |a 37669040
|2 pmid
024 7 _ |a WOS:001062618600001
|2 WOS
024 7 _ |a openalex:W4386439019
|2 openalex
037 _ _ |a PUBDB-2023-08014
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Roehrig, Susanne
|0 P:(DE-HGF)0
|b 0
|e Corresponding author
245 _ _ |a Design and Preclinical Characterization Program toward Asundexian (BAY 2433334), an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic Disorders
260 _ _ |a Washington, DC
|c 2023
|b ACS
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1704373539_2679099
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Activated coagulation factor XI (FXIa) is a highly attractive antithrombotic target as it contributes to the development and progression of thrombosis but is thought to play only a minor role in hemostasis so that its inhibition may allow for decoupling of antithrombotic efficacy and bleeding time prolongation. Herein, we report our major efforts to identify an orally bioavailable, reversible FXIa inhibitor. Using a protein structure-based de novo design approach, we identified a novel micromolar hit with attractive physicochemical properties. During lead modification, a critical problem was balancing potency and absorption by focusing on the most important interactions of the lead series with FXIa while simultaneously seeking to improve metabolic stability and the cytochrome P450 interaction profile. In clinical trials, the resulting compound from our extensive research program, asundexian (BAY 2433334), proved to possess the desired DMPK properties for once-daily oral dosing, and even more importantly, the initial pharmacological hypothesis was confirmed.
536 _ _ |a 6G3 - PETRA III (DESY) (POF4-6G3)
|0 G:(DE-HGF)POF4-6G3
|c POF4-6G3
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: bib-pubdb1.desy.de
693 _ _ |a PETRA III
|f PETRA Beamline P14
|1 EXP:(DE-H253)PETRAIII-20150101
|0 EXP:(DE-H253)P-P14-20150101
|6 EXP:(DE-H253)P-P14-20150101
|x 0
700 1 _ |a Ackerstaff, Jens
|b 1
700 1 _ |a Jiménez Núñez, Eloísa
|b 2
700 1 _ |a Teller, Henrik
|b 3
700 1 _ |a Ellerbrock, Pascal
|b 4
700 1 _ |a Meier, Katharina
|b 5
700 1 _ |a Heitmeier, Stefan
|b 6
700 1 _ |a Tersteegen, Adrian
|b 7
700 1 _ |a Stampfuss, Jan
|b 8
700 1 _ |a Lang, Dieter
|0 0000-0002-2968-638X
|b 9
700 1 _ |a Schlemmer, Karl-Heinz
|b 10
700 1 _ |a Schaefer, Martina
|b 11
700 1 _ |a Gericke, Kersten M.
|b 12
700 1 _ |a Kinzel, Tom
|b 13
700 1 _ |a Meibom, Daniel
|0 0000-0003-4978-9842
|b 14
700 1 _ |a Schmidt, Martina
|b 15
700 1 _ |a Gerdes, Christoph
|b 16
700 1 _ |a Follmann, Markus
|0 0000-0003-1246-3603
|b 17
700 1 _ |a Hillisch, Alexander
|0 0000-0002-4228-2347
|b 18
773 _ _ |a 10.1021/acs.jmedchem.3c00795
|g Vol. 66, no. 17, p. 12203 - 12224
|0 PERI:(DE-600)1491411-6
|n 17
|p 12203 - 12224
|t Journal of medicinal chemistry
|v 66
|y 2023
|x 0095-9065
856 4 _ |u https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.3c00795
856 4 _ |u https://bib-pubdb1.desy.de/record/600501/files/Design%20and%20Preclinical%20Characterization%20HILLISCH%20P14.pdf
|y OpenAccess
856 4 _ |u https://bib-pubdb1.desy.de/record/600501/files/Design%20and%20Preclinical%20Characterization%20HILLISCH%20P14.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:bib-pubdb1.desy.de:600501
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
913 1 _ |a DE-HGF
|b Forschungsbereich Materie
|l Großgeräte: Materie
|1 G:(DE-HGF)POF4-6G0
|0 G:(DE-HGF)POF4-6G3
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-600
|4 G:(DE-HGF)POF
|v PETRA III (DESY)
|x 0
914 1 _ |y 2023
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1200
|2 StatID
|b Chemical Reactions
|d 2023-10-21
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b J MED CHEM : 2022
|d 2023-10-21
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1210
|2 StatID
|b Index Chemicus
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-21
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-21
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J MED CHEM : 2022
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-21
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-10-21
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-21
920 1 _ |0 I:(DE-H253)EMBL-User-20120814
|k EMBL-User
|l EMBL-User
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-H253)EMBL-User-20120814
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21